StockNews.com initiated coverage on shares of OncoCyte (NASDAQ:OCX – Free Report) in a research note published on Tuesday. The brokerage issued a sell rating on the stock.
Separately, Needham & Company LLC reaffirmed a buy rating and issued a $4.25 price target on shares of OncoCyte in a research report on Friday, August 9th. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the stock. According to MarketBeat, OncoCyte presently has an average rating of Hold and an average target price of $4.06.
Get Our Latest Stock Report on OCX
OncoCyte Stock Performance
OncoCyte (NASDAQ:OCX – Get Free Report) last issued its earnings results on Thursday, August 8th. The company reported ($0.36) EPS for the quarter. The company had revenue of $0.10 million during the quarter. OncoCyte had a negative return on equity of 149.88% and a negative net margin of 3,558.46%. On average, analysts expect that OncoCyte will post -2.58 EPS for the current fiscal year.
About OncoCyte
OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.
Read More
- Five stocks we like better than OncoCyte
- Breakout Stocks: What They Are and How to Identify Them
- Does GTA VI Make Take-Two Interactive Stock an Irresistible Buy?
- How to Choose Top Rated Stocks
- Why HPE’s Dip Is a Prime Opportunity for Blue-Chip AI Investors
- Election Stocks: How Elections Affect the Stock Market
- Why Analysts See Big Upside for Occidental Petroleum Despite Lows
Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with MarketBeat.com's FREE daily email newsletter.